ATMP Sweden 2026 brings academia, healthcare and industry together around a single question: what needs to change for advanced therapies to reach patients at scale?

Over two days the programme covers emerging science from Swedish and Nordic research groups, regulatory and manufacturing routes that carry it toward the clinic, the trial infrastructure and capability that puts it in front of patients, and the funding and reimbursement models that decide whether it stays there. Throughout it all are the translational journeys behind the field, successes and failures alike, and the patient voices that gives the work purpose.

From discovery to delivery: Advancing ATMPs to patients

The 2026 programme will span the breadth of the field. Topics include Sweden’s and the Nordics’ place in the global ATMP landscape, the frontiers of cell and gene therapy emerging from our universities, and the regulatory pathways shaping accelerated development across the Nordics and the EU. They extend to the realities of clinical advancement, including some of the most demanding indications; the manufacturing and translation that make these therapies possible; and the funding, pricing, and policy questions that decide whether innovation reaches patients at scale. The patient voice, the networks connecting discovery to delivery, and the next generation of scientists are woven across the programme.

Speakers will include leading figures from across the field, drawn from institutions such as Karolinska Institutet, Lund University, and Uppsala University, alongside regulators, clinicians, and the industry which driving the field forward. A dedicated poster session will spotlight emerging ATMP science.

25% discount for NLS Members

Access an exclusive 25% discount for NLS Members.

To access your member discount, please contact Mattias Olme,
+46 8 588 941 51
mattias@nlsnews.com

learn more and register here